No document available.
Keywords :
Acarbose; Blood Glucose/metabolism; Diabetes Mellitus, Type 1/blood/drug therapy; Diabetes Mellitus, Type 2/blood/drug therapy; Eating; Humans; Hypoglycemia/drug therapy/prevention & control; Hypoglycemic Agents/therapeutic use; Sulfonylurea Compounds/therapeutic use; Trisaccharides/pharmacology/therapeutic use; alpha-Glucosidases/antagonists & inhibitors
Abstract :
[en] This paper reviews the use of acarbose in the prevention and treatment of hypoglycaemia. In diet- or sulfonylurea-treated patients, acarbose may reduce the incidence of late postprandial hypoglycaemia. In insulin-treated patients, acarbose treatment usually requires reduction of the insulin dose; one study has shown that 100 mg acarbose at night significantly reduces the incidence of mid-evening and nocturnal hypoglycaemia. Several studies have suggested acarbose to be a useful adjunct to the management of reactive hypoglycaemia in the non-diabetic patients. Long-term prospective studies are still needed to document this last indication of acarbose or other alpha-glycosidase inhibitors.
Scopus citations®
without self-citations
39